Cargando…

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis

Therapeutic drug monitoring of Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) is based on a complex procedure and is therefore not possible in most laboratories, especially in emergency cases. This work addresses the question of whether therapeutic drug monitoring of nabiximols can be perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birke, Rüdiger, Meister, Stefanie, Winkelmann, Alexander, Hinz, Burkhard, Walther, Udo I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267351/ https://www.ncbi.nlm.nih.gov/pubmed/35807001 http://dx.doi.org/10.3390/jcm11133717

Ejemplares similares

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
por: Twelves, Chris, et al.
Publicado: (2021)

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
por: Pau, Massimiliano, et al.
Publicado: (2022)

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
por: Chisari, Clara Grazia, et al.
Publicado: (2023)

Cannabinoids as anticancer drugs: current status of preclinical research
por: Hinz, Burkhard, et al.
Publicado: (2022)

Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
por: Ramer, Robert, et al.
Publicado: (2022)

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
por: Guger, Michael, et al.
Publicado: (2023)

A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’
por: Patti, Francesco, et al.
Publicado: (2022)

Impact of Cannabinoid Compounds on Skin Cancer
por: Ramer, Robert, et al.
Publicado: (2022)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
por: Schwittay, Maximilian A., et al.
Publicado: (2021)

Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study
por: Rosa, Gian Marco, et al.
Publicado: (2022)

The Determination of Cannabinoids in Urine Samples Using Microextraction by Packed Sorbent and Gas Chromatography-Mass Spectrometry
por: Rosendo, Luana M., et al.
Publicado: (2022)

Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2
por: Scholl, Antje, et al.
Publicado: (2016)

Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway
por: Walther, Udo, et al.
Publicado: (2016)

Analysis of Cannabinoids and Metabolites in Dried Urine Spots (DUS)
por: Moretti, Matteo, et al.
Publicado: (2021)

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
por: Trigo, Jose M., et al.
Publicado: (2018)

Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
por: Kanaan, Ahmad Seif, et al.
Publicado: (2017)

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
por: Mills, Llewellyn, et al.
Publicado: (2022)

Cannabinoid-Induced Autophagy and Heme Oxygenase-1 Determine the Fate of Adipose Tissue-Derived Mesenchymal Stem Cells under Stressful Conditions
por: Bublitz, Katharina, et al.
Publicado: (2020)

Urine Caffeine Concentration in Doping Control Samples from 2004 to 2015
por: Aguilar-Navarro, Millán, et al.
Publicado: (2019)

Influence of Test Specimen Geometry and Water Soaking on the In Vitro Cytotoxicity of Orthocryl(®), Orthocryl(®) LC, Loctite(®) EA 9483 and Polypropylene
por: Behnke, Richard, et al.
Publicado: (2022)

Cannabinoids in the management of spasticity associated with multiple sclerosis
por: Malfitano, Anna Maria, et al.
Publicado: (2008)

STEADI-RX: ADAPTING CDC’S STEADI INITIATIVE FOR USE IN COMMUNITY PHARMACIES
por: Burns, Elizabeth R, et al.
Publicado: (2019)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?
por: Claus, Benedikt Bernd, et al.
Publicado: (2020)

Screening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC–QTOF–MS
por: Gundersen, Per Ole M., et al.
Publicado: (2018)

Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: Diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrations
por: Bouzas, Lorena, et al.
Publicado: (2010)

Quantitative analysis of opioids and cannabinoids in wastewater samples
por: Jacox, Alethea, et al.
Publicado: (2017)

Steady state oscillations of circular currents in concentric polariton condensates
por: Lukoshkin, Vladimir, et al.
Publicado: (2023)

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data
por: Walther, Sebastian, et al.
Publicado: (2010)

Programmable dynamic steady states in ATP-driven nonequilibrium DNA systems
por: Heinen, Laura, et al.
Publicado: (2019)

Variation in Cannabinoid Metabolites Present in the Urine of Adults Using Medical Cannabis Products in Massachusetts
por: Gilman, Jodi M., et al.
Publicado: (2021)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
por: Gado, Francesca, et al.
Publicado: (2018)

Urine color as an indicator of urine concentration in pregnant and lactating women
por: McKenzie, Amy L., et al.
Publicado: (2015)

Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low
por: Heinonen, E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpfoqjh9jbk6q0kqa82s52klr3